Lonnel Coats, Lexicon Pharmaceuticals CEO
Lexicon hops on public offering train to prepare for next year's potential drug approval
Public offerings and private placements have for years been part of the lexicon for Nasdaq-listed biopharmas, but they’ve become more prominent amid a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
